Gam-COVID-Vac

BIOLOGICAL9 trials

Conditions

Adverse Reaction to VaccineCOVID-19COVID-19 PreventionCOVID19 VaccineCoronavirus InfectionCovid19Covid19 PreventionPreventive Immunization COVID-19

Phase 1

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug Gam-COVID-Vac Vaccine Against COVID-19

CompletedNCT04436471

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationPreventive Immunization COVID-19

Start: 2020-06-17End: 2020-08-10Updated: 2020-08-12

Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray

NCT05248373

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationCOVID-19, SARS-CoV-2 Acute Respiratory Disease

Start: 2022-03-08End: 2023-12-30Target: 400Updated: 2022-03-08

Phase 2

The Study of Gam-COVID-Vac Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older

NCT04587219

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationCoronavirus Infection

Start: 2020-10-22End: 2021-04-30Updated: 2021-01-22

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

NCT04640233

Dr. Reddy's Laboratories LimitedCOVID-19 Prevention

Start: 2020-11-30End: 2021-09-30Updated: 2021-06-02

Phase 3

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19

NCT04530396

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationCovid19 Prevention

Start: 2020-09-07End: 2021-05-01Updated: 2021-01-22

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus

NCT04564716

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationCovid19

Start: 2020-09-28End: 2021-04-10Updated: 2020-12-02

Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela

NCT04642339

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationCovid19

Start: 2020-11-30End: 2021-12-31Target: 2000Updated: 2020-11-24

A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE

NCT04656613

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationCovid19, SARS-CoV Infection

Start: 2020-12-31End: 2021-12-31Target: 1000Updated: 2020-12-07

Unknown Phase

COVID-19 Vaccines Safety Tracking (CoVaST)

RecruitingNCT04834869

Masaryk UniversityAdverse Reaction to Vaccine, COVID19 Vaccine

Start: 2021-04-01End: 2026-12-31Target: 30000Updated: 2022-04-06

Vaccine X2025-07-291 citations

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2023-11-1548 citations

COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects

International Journal of Environmental Research and Public Health2021-07-2568 citations

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Molecular Therapy2021-04-2357 citations

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

2021-02-021133 citations

International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation

Russian Journal of Preventive Medicine2021-01-011 citations

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

2020-09-04686 citations